| Stage | MDLZ | % of rev | BRBR | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $10.0B | 100.00% | $570M | 100.00% | MDLZ ×17.47 |
| Gross profit | $3.9B | 39.37% | $163M | 28.63% | MDLZ +10.7pp |
| Operating income | $1.8B | 17.64% | $65M | 11.47% | MDLZ +6.2pp |
| Pre-tax income | $1.7B | 17.27% | $46M | 7.98% | MDLZ +9.3pp |
| Net income | $1.3B | 13.12% | $34M | 6.00% | MDLZ +7.1pp |
| Stage | MDLZ | BRBR | Gap · A − B |
|---|---|---|---|
| Revenue | $10.0B100.00% | $570M100.00% | MDLZ ×17.47 |
| Gross profit | 39.37%$3.9B | 28.63%$163M | MDLZ +10.7pp |
| Operating income | 17.64%$1.8B | 11.47%$65M | MDLZ +6.2pp |
| Pre-tax income | 17.27%$1.7B | 7.98%$46M | MDLZ +9.3pp |
| Net income | 13.12%$1.3B | 6.00%$34M | MDLZ +7.1pp |
None
No disclosed counterparties: MDLZ.